AIA Hong Kong has signed an agreement with ACT Genomics that brings ACT Genomics' leading cancer genomic testing services to AIA Hong Kong customers at a privileged rate. This technology-driven service can help AIA Hong Kong customers in need to receive appropriate cancer treatment solutions based on their personalised cancer genomic information. The privileged rate is available to customers of selected AIA Hong Kong's medical plans, including AIA VHIS Flexi Scheme^#, AIA VHIS Prime Scheme, AIA CEO & CEO Essence Series and AIA Super Good Health Series*. This collaboration further exemplifies AIA Hong Kong's commitment to offering customers value-added access to quality medical care to support them through their healthcare journey.

Mr. Ip Man Kit, Chief Technology & Operations Officer of AIA Hong Kong & Macau, said, “AIA Hong Kong's collaboration with the cancer genomic test provider aims to take medical insurance cover to a new level by assisting customers to utilise their financial resources more efficiently in obtaining optimal medical treatment. This collaboration is yet another testament to our commitment to the ‘customer-centric' philosophy, demonstrating our brand promise to help people live healthier, longer, better lives.”

Dr. York Chow, Chief Medical Officer and Corporate Advisor of AIA Hong Kong & Macau, said, “With recent advances in medical technology, most cancers are treatable or controllable with appropriate treatment. Cancer genomic test is an effective tool to help patients in the shortest time possible to decide on the most suitable medical therapy with predictable response based on their cancer genetic information. By supporting the practice of ‘Precision Medicine' - identify the right treatment to target the tumour cells - as early as possible, can help cancer patients to achieve the best outcome.”

Dr. Chen Hua Chien, Chief Executive Officer of ACT Genomics, said, “Our collaboration with AIA Hong Kong helps more cancer patients to benefit from better cancer treatment and monitoring with more accurate diagnosis on a personal genetic level. Such technology enables cancer patients to get effective diagnosis and treatment options at early stage resulting in higher chance of recovery. With our Next Generation Sequencing (NGS) laboratory opened at the Hong Kong Science Park, we are committed to working with partners to provide the best services and again, to turn ‘genomics into action', which is our company philosophy.”

About ACT Genomics' Personalised Genomic Information Based-Treatment 
ACT Genomics Holdings Co., Ltd, a Hong Kong Science and Technology Parks Corporation (HKSTP) partner company, provides cancer patients with personalised genomic information based-treatment plans through its cutting-edge Next Generation Sequencing (NGS) platform, medical reports and integrated services. The platform, which is capable of detecting multiple genomic alterations using a single tissue sample within a single test run, provides physicians with an essential reference for selecting the most appropriate and effective treatment for a patient. It transforms the existing cancer treatment model and makes cancer more manageable.

About AIA Hong Kong and AIA Macau
AIA Hong Kong and AIA Macau are subsidiaries of AIA Group Limited. AIA Group Limited established its operations in Hong Kong in 1931. To date, we have over 16,500 AIA financial planners¹, as well as an extensive network of brokerage and bancassurance partners. We serve over 3 million customers², offering them a wide selection of professional services and products ranging from individual life, group life, accident, medical and health, mandatory provident fund, personal lines insurance to investment-linked products with numerous investment options. We are also dedicated to providing superb product solutions to meet the financial needs of high net worth customers.

¹ as at February 2019
² as at 31 March 2018

About AIA
AIA Group Limited and its subsidiaries (collectively “AIA” or the “Group”) comprise the largest independent publicly listed pan-Asian life insurance group. It has a presence in 18 markets in Asia-Pacific – wholly-owned branches and subsidiaries in Hong Kong, Thailand, Singapore, Malaysia, China, Korea, the Philippines, Australia, Indonesia, Taiwan, Vietnam, New Zealand, Macau, Brunei, Cambodia, a 97 per cent subsidiary in Sri Lanka, a 49 per cent joint venture in India and a representative office in Myanmar.

The business that is now AIA was first established in Shanghai a century ago in 1919. It is a market leader in the Asia-Pacific region (ex-Japan) based on life insurance premiums and holds leading positions across the majority of its markets. It had total assets of US$230 billion as of 31 December 2018.

AIA meets the long-term savings and protection needs of individuals by offering a range of products and services including life insurance, accident and health insurance and savings plans. The Group also provides employee benefits, credit life and pension services to corporate clients. Through an extensive network of agents, partners and employees across Asia-Pacific, AIA serves the holders of more than 33 million individual policies and over 16 million participating members of group insurance schemes.

AIA Group Limited is listed on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code “1299” with American Depositary Receipts (Level 1) traded on the over-the-counter market (ticker symbol: “AAGIY”).

About ACT Genomics
ACT Genomics Holdings Co., Ltd, a Hong Kong Science and Technology Parks Corporation (HKSTP) partner company, is an innovation-driven cancer solution provider in Asia with offices in Hong Kong, Taiwan, Singapore and Japan. With its Next Generation Sequencing (NGS) technology and experienced bioinformatics team, it provides optimal cancer treatment planning, cancer relapse and drug resistance monitoring, cancer risk assessment and immunotherapy evaluation to medical professionals. Its team specialises in biomarker identification, underlying disease mechanism discovery and genetic alteration exploration. Pharmaceutical communities also benefit from its expertise in identifying targets for drug development, stratifying patients for clinical studies and delineating drug responses. For more information, please visit www.actgenomics.com.